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Abstract
Background: Adherence to HIV antiretroviral therapy (ART) among children in developing settings is poorly understood.
Methodology/Principal Findings: To understand the level, distribution, and correlates of ART adherence behavior, we
prospectively determined monthly ART adherence through multiple measures and six-monthly HIV RNA levels among 121
Ugandan children aged 2–10 years for one year. Median adherence levels were 100% by three-day recall, 97.4% by 30-day
visual analog scale, 97.3% by unannounced pill count/liquid formulation weights, and 96.3% by medication event monitors
(MEMS). Interruptions in MEMS adherence of $48 hours were seen in 57.0% of children; 36.3% had detectable HIV RNA at
one year. Only MEMS correlated significantly with HIV RNA levels (r=20.25, p=0.04). Multivariable regression found the
following to be associated with ,90% MEMS adherence: hospitalization of child (adjusted odds ratio [AOR] 3.0, 95%
confidence interval [CI] 1.6–5.5; p=0.001), liquid formulation use (AOR 1.4, 95%CI 1.0–2.0; p=0.04), and caregiver’s alcohol
use (AOR 3.1, 95%CI 1.8–5.2; p,0.0001). Child’s use of co-trimoxazole (AOR 0.5, 95%CI 0.4–0.9; p=0.009), caregiver’s use of
ART (AOR 0.6, 95%CI 0.4–0.9; p=0.03), possible caregiver depression (AOR 0.6, 95%CI 0.4–0.8; p=0.001), and caregiver
feeling ashamed of child’s HIV status (AOR 0.5, 95%CI 0.3–0.6; p,0.0001) were protective against ,90% MEMS adherence.
Change in drug manufacturer (AOR 4.1, 95%CI 1.5–11.5; p=0.009) and caregiver’s alcohol use (AOR 5.5, 95%CI 2.8–10.7;
p,0.0001) were associated with $48-hour interruptions by MEMS, while second-line ART (AOR 0.3, 95%CI 0.1–0.99;
p=0.049) and increasing assets (AOR 0.7, 95%CI 0.6–0.9; p=0.0007) were protective against these interruptions.
Conclusions/Significance: Adherence success depends on a well-established medication taking routine, including caregiver
support and adequate education on medication changes. Caregiver-reported depression and shame may reflect fear of poor
outcomes, functioning as motivation for the child to adhere. Further research is needed to better understand and build on
these key influential factors for adherence intervention development.
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Introduction
As of the end of 2009, an estimated 2.5 million children were
living with HIV/AIDS globally, and 354,000 were receiving
antiretroviral therapy (ART) [1]. Studies to date on adherence to
ART among pediatric populations in developing settings have
shown mixed results with adherence ranging from 49% to 100%
[2]. Factors related to family structure [3,4], socioeconomic status
[3,5], disclosure [5,6,7,8], hospitalization [8] and medication
routine and/or regimen [4,5,9] have all been significantly
associated with ART adherence. Most studies have relied on
caregiver-report [3,4,5,9,10,11,12], although some studies have
used objective measures such as pill counts [5,8,12,13], pharmacy
records [14], therapeutic drug monitoring [15], directly observed
therapy [16], and electronic monitoring [5,7,17]. Few have
compared multiple adherence measures to HIV RNA [5,17].
Variations in measures and in adherence estimates call for a more
comprehensive and accurate assessment of adherence to ART in
this population in order to develop evidence-based interventions
for promoting sustained adherence.
This observational study prospectively measured adherence
using caregiver report, unannounced pill count/weight of liquid
formulations, and medication event monitors (MEMS) in 121
children taking ART in rural, southwestern Uganda. Following an
adaptation of a previously published conceptual framework for
understanding pediatric adherence behavior [18], associations
were examined among adherence and various child, antiretroviral
(ARV) regimen, caregiver, and household/community character-
istics. This study adds to the current literature by comparing
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36737multiple adherence measures, including HIV RNA, which were
collected over one year in a relatively large sample receiving
routine clinical care. The primary objectives of the study were to
determine the levels, distribution, and correlates of ART
adherence among children in a developing setting. A secondary
objective was to determine which measure correlates best with
HIV RNA levels and is most feasible in a developing setting.
Methods
Ethical Statement
This study was registered with Clinical Trials (NCT00868257)
and was approved by institutional review boards at the Mbarara
University of Science and Technology, the Uganda National
Council for Science and Technology, and Partners Healthcare (see
Protocol S1). Written, informed consent was obtained from all
caregivers, and verbal assent was obtained from children at least
seven years old.
Study Setting and Population
The participants in this study were recruited from the
Children’s HIV/AIDS Care Clinic at the Mbarara University
Regional Referral Hospital, which serves a largely rural popula-
tion in southwestern Uganda. Approximately 700 children are
actively followed in the clinic with 520 taking ART, which is
provided free-of-charge and according to Ugandan National
Guidelines [19]. No changes in the Ugandan National Guidelines
occurred during the course of the study. All ARVs were dispensed
by the hospital pharmacy. Children were eligible for this study if
they were aged 2–10 years old, HIV-positive, already taking ART
or initiating ART at enrollment, and residing within 20 km of the
clinic, beyond which logistics of data collection would not have
been possible. Children aged 2–10 years were targeted because
this age range represents a large proportion of HIV-infected
children in care [20,21], and the requirements for care within this
age range are relatively similar and distinct from those for infants
and adolescents [18]. The only exclusion criterion was residence at
a boarding school, which would have presented substantially
different circumstances of adherence behavior compared to
children living at home. All eligible participants identified between
July 2008 and February 2009 were recruited for the study; data
were collected between July 2008 and March 2010.
Adherence Measures
Adherence was measured monthly by three methods: 1)
caregiver report, using three-day recall and 30-day visual analog
scale [VAS]); 2) unannounced pill count/weight of liquid
formulations at the child’s home, the timing of which was variable
within a two to six week period to avoid predictability; and 3) the
medication event monitoring system (MEMS), which recorded
bottle openings for both pill and liquid formulations. Adherence
by pill count was calculated as (the number of pills dispensed –
number of pills counted)/(the number of pills expected to be taken)
in the previous month. A similar calculation was used for liquid
formulations, substituting grams for pills; the weight of the
medication bottle was subtracted from measured weights to
determine the weight of the medication present. MEMS adher-
ence was calculated as (the number of events/the number of
expected events) * 100. The timing of the opening was not
considered in the calculation, as the contribution of dose timing to
viral suppression is controversial [17,22] and MEMS events may
or may not correlate precisely with medication ingestion (i.e.
participants may remove multiple doses at one opening or open
the bottle without removing medication). MEMS data was also
reviewed for $48-hour interruptions, which have been shown to
predict virologic failure and resistance to non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based therapy [23,24].
Child, Arv Regimen, Caregiver, and Household/
Community Characteristics
A research assistant administered a structured interview to
participant caregivers at baseline and every three months over the
one-year study period. All questions were translated into the local
language (Runyankole) and back translated to ensure proper
interpretation. The interview covered various socio-demographic,
behavioral, and clinical factors with potential to influence
adherence behavior (see Table 1), and included the following
standardized measures: 1) Caregiver depressive symptoms were
assessed using the Hopkins Symptom Checklist Depression Scale
(with a cut off for possible depression defined as a score $1.75),
which was found to have criterion validity with a grief syndrome in
neighboring Rwanda [25]; 2) Physical symptoms were measured
with a scale drawn from the AIDS Clinical Trials Group symptom
survey [26]; 3) Quality of life was examined in caregivers by the
physical and mental health component summary scales of the
Short-Form 12 version 2 (SF-12v2; standardized to a mean of 50
based on the US population) [27] and in children aged five and
older by the Pediatric AIDS Clinical Trials Group (PACTG)
Quality of Life Assessment, which includes general health
perception, symptom distress, psychological status, and physical
function domains (each standardized to a range of 0–100) [28].
ARV regimen characteristics were recorded during the monthly
unannounced pill counts/liquid formulation weights.
Laboratory Tests
National Guidelines at the time of the study recommended CD4
percentages and HIV RNA levels every six months as part of
standard clinical care. When performed, these values were
matched with adherence data determined at baseline, six months,
and/or 12 months, if they were drawn within six weeks before or
after the time point. CD4 percentages were measured by standard
flow cytometry techniques (FACSCount, BD, New Jersey, USA).
HIV RNA levels were determined by the Amplicor HIV-1
Monitor Test (Roche, New Jersey, USA) with a lower limit of
detection of 400 copies/ml.
Analysis Methods
Monthly adherence values were analyzed as continuous
variables; averaged (mean) data were determined for each
participant and reported as medians for the entire cohort. MEMS
data were censored for known device non-use, including periods
with a non-functional MEMS cap or where the caregiver reported
not using the device (e.g. while traveling). Assuming a standard
deviation of 9, the sample size of 121 has .80% power to detect
an adherence level of 90.0+/21.7%.
Nonparametric statistical tests were used, given the non-normal
distribution of the data. Wilcoxon signed rank and Chi-square tests
were used for bivariable comparisons of continuous and categor-
ical adherence measures, respectively. Agreement among adher-
ence measures and HIV RNA was determined by Spearman
correlation at six and twelve months. Adherence data were
compared with each other using data from the full one-year study
period; comparisons with HIV RNA reflect the month prior to the
HIV RNA test.
A principal component analysis was performed to create an
asset index serving as a proxy for socio-economic status. This
index is based on the methodology of Filmer-Pritchett [29] and
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ownership, good transport, and food security.
Predictors of adherence were determined by generalized linear
mixed models (SAS proc glimmix), first using univariable
regressions on ,90% MEMS adherence for the full study period.
This level of adherence was chosen because reliable viral
suppression in NNRTI-based regimens is unlikely at lower levels
of adherence [30], and it is consistent with the levels of adherence
assessed in previous studies (85%, 95%, and 100%) [2]. If the p-
value was found to be ,0.10, the predictor was retained for
multivariable analysis. A second multivariable regression was
similarly examined for the presence of $48 hour interruptions in
MEMS adherence data. The following variables were examined
(selected from Table 1): child characteristics (age, gender, ART
history, enrollment CD4 percentage, hospitalization in the pre-
vious three months, presence of physical symptoms, quality of life,
attending school, use of co-trimoxazole, knowledge of HIV status);
regimen characteristics (use of liquid formulation at least once,
change in drug manufacturer or formulation at least once, use of
second line ART); caregiver characteristics (biological relationship
to the child, change in primary caregiver, HIV status, use of ART,
education level, employment status, possible depression, physical
and mental health, use of alcohol, more than one caregiver, hiding
the child’s HIV status, feeling ashamed and having difficulty
telling others about the child’s HIV status); and household
characteristics (place to keep ART, time and cost of travel to
clinic, number of household members, asset index, having to sell
property, disclosure of child’s HIV status within the household and
to the community).
All analyses were performed using SAS (version 9.2, Cary, NC,
USA). With the exception of the multivariable regression model,
Table 1. Characteristics of the child, regimen, caregiver, and household/community.
Child characteristics N* Caregiver characteristics N*
Median age 120 5.2 years (IQR 3.6–7.2) Biologic mother or father 119 84 (70.6%)
Age 5 years or older 120 65 (54.2%) Female 121 104 (86.0%)
Female 118 56 (47.5%) Change in caregiver 121 6 (5.0%)
ART experience at enrollment 121 105 (86.8%) HIV infected 120 89 (74.2%)
Median duration of ART 85 26 months (IQR 11.5–41.8) Taking ART 119 32 (26.7%)
Median CD4% 107 40% (IQR 28%–48%) Greater than primary school education 121 38 (31.4%)
HIV RNA ,400 copies/ml 91 53 (58.2%) Employed 121 75 (62.0%)
ART initiated at enrollment 121 16 (13.2%) Possible depression
3 120 30 (25.0%)
Median CD4% 14 27% (16%–32%) SF-12v2: Physical composite score 117 53.8 (IQR 48.9–55.9)
Hospitalized in the past three months 111 6 (5.4%) SF-12v2: Mental composite score 117 49.0 (IQR 41.6–54.7)
Received PMTCT 89 4 (4.5%) Any alcohol use 120 11 (9.2%)
Physical symptoms reported
1 116 41 (35.3%) Heavy alcohol use
4 120 4 (3.3%)
Median # of symptoms reported, if any 41 2 (IQR 1–3) Help available with the child 119 75 (63.0%)
Attending (pre)school, if aged 5 or older 63 41 (65.1%) More than one person gives ART to the child 117 34 (29.1%)
PACTG quality of life Difficulty telling others about the child’s HIV 116 84 (72.4%)
Median general health perception 104 81.0 (IQR 66.7–88.9) Ashamed of the child’s HIV status 115 69 (60.0%)
Median symptom distress 97 71.4 (IQR 64.3–78.6) Hides the child’s HIV status 116 80 (69.0%)
Median psychological status 98 96.4 (IQR 89.3–100.0) Household/community characteristics
Median physical functioning 99 100.0 (IQR 95.8–100.0) Place to keep ART 100 97 (97.0%)
Use of co-trimoxazole
2 113 95 (84.1%) Median asset index 111 0.5 (IQR -1.7–1.4)
Knowledge of HIV status 120 18 (15.0%) Median minutes traveled to clinic 120 30 (20–60)
Regimen characteristics Median cost of travel to clinic 119 4000 UgSh (2000–7000)
5
NNRTI backbone 121 114 (94.2%) Median # of siblings 121 2 (IQR 1–3)
PI backbone 121 7 (5.8%) Median # of siblings with HIV 121 1 (IQR 0–1)
Liquid formulation used at least once 121 42 (34.7%) Median # of other children in household 121 0 (IQR 0–2)
Change in ARV manufacturer at least
once
121 99 (81.8%) Median # of other children in household with HIV121 0 (IQR 0–1)
Change in ARV formulation at least once121 16 (13.2%) Disclosure of child’s HIV to the household 115 109 (94.8%)
Use of a 2-drug FDC at least once 121 23 (19.0%) Disclosure of child’s HIV to the community 115 70 (60.9%)
Use of a 3-drug FDC at least once 121 10 (8.3%)
*N=sample used for determining each characteristic, IQR=interquartile range, FDC=fixed drug combination, UgSh=Ugandan Shillings.
1Most common symptoms were cough, weakness/tiredness, and skin problems.
2Co-trimoxazole was prescribed to all children on enrollment for prevention of opportunistic and other infections regardless of ARV use.
3The most common and consistently endorsed symptom on this scale was ‘‘worrying too much about things’’.
4Defined as .5 drinks (1 glass wine, 333 ml beer, or 40 ml hard liquor).
54000 UgSh equals approximately US$1.60.
doi:10.1371/journal.pone.0036737.t001
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as missing.
Results
Study Participants
A total of 158 caregivers were approached for participation in
this study, of whom five (3.2%) refused participation and 32
(20.3%) were found to be ineligible (Figure 1). The most common
reason for ineligibility was residence beyond 20 km from the clinic.
The first 121 children eligible for participation were enrolled in the
study. The baseline characteristics of the children, ARV regimens,
caregivers, and households/communities are detailed in Table 1.
Briefly, most children were taking NNRTI-based ART at
enrollment and were clinically stable. Most caregivers were the
biological mother with limited education and were HIV-infected
themselves. Nearly all households were aware of the child’s HIV
status, but most children did not know they were HIV-infected.
Ten children left the study (five moved out of the study
catchment area, two changed caregivers and the new caregivers
were not interested in participating, and two caregivers changed
their minds about participating in the study; one child’s caregiver
exhibited disruptive behavior), and one child died of diarrheal
illness near the end of the study. Data for these 11 children were
censored at the time they left the study. When comparing the
children who left and did not leave the study, no differences were
seen in child, caregiver, or baseline regimen characteristics.
Households, however, were significantly smaller in children who
left (mean 2.5 versus 4.5 members, p=0.004) with fewer other
children with HIV (mean 0 versus 0.3 children, p=0,0.001). No
children were lost to follow up. No adverse events were reported.
HIV RNA Levels
Detectable HIV RNA (defined as .400 copies/ml) is shown in
Figure 2. Fewer than 5% of detectable HIV RNA levels were
,1,000 copies/ml, making the likelihood of transient, minor
elevations, or ‘‘blips’’, low [31]. Among participants already taking
ART at baseline, levels of detectable HIV RNA remained
essentially unchanged with 41.8%, 36.7%, and 38.2% at 0, 6,
and 12 months, respectively. Among participants initiating ART
at baseline, levels of detectable HIV RNA were 100.0%, 38.5%
and 25.0% at 0, 6, and 12 months, respectively. HIV RNA values
were missing for 18 (14.9%), 35 (28.9%), and 31 (25.6%)
participants at 0, 6, and 12 months, respectively. These samples
were not drawn due to sporadic variances in routine clinical care
and were not systematically missed.
Median Adherence and Adherence Patterns
Median adherence for the cohort was high by all measures,
ranging from 96.3 to 100.0% (Table 2). Midway through the
study, hospital pharmacists were found to be taking back and
giving out extra medication in efforts to facilitate adherence
among their patients. The number of participants affected by their
efforts and the extent of the medication manipulation was not
recorded, thus preventing adjustment of the unannounced pill
counts/liquid weights. MEMS data were censored for known
device non-use at least once in 32 participants (26.4%), with the
censored data accounting for 4.6% of all monthly MEMS
measurements. Median adherence levels for all measurement
methods did not differ between children who were already taking
ART and those who initiated ART at enrollment (Wilcoxon
signed rank tests, p=0.18–0.79), and median adherence did not
change significantly over time (Wilcoxon signed rank test,
p=0.35). Median participant adherence clustered between 90%
and 100% by all measures (Table 3); however, there were
differences in the distribution of adherence for each measure.
There were significantly more participants with ,90% adherence
by MEMS than three-day recall (29.6% versus 3.3%; p=,0.001).
Median adherence among the ten children who left the study was
100.0% (IQR 100.0–100.0%) by three-day recall, 97.5% (IQR
93.8–100.0%) by 30-day VAS, 81.5% (IQR 80.8–85.9%) by
unannounced pill counts/liquid formulation weights, and 84.6%
(IQR 72.6–91.3%) by MEMS prior to disenrollment.
Despite the high median values, interruptions in adherence
were commonly detected by MEMS data. Sixty-nine children
(57.0%) had periods in which their MEMS cap was not opened for
$48 hours with a median of two such periods per child (IQR 1–5).
The duration of these periods lasted a median of 106 hours (IQR
60–204). Analyzing children with both MEMS data and HIV
RNA levels available at 12 months, 17 (44.7%) children with $48
hour interruptions and 12 (27.9%) children with no $48 hour
interruptions had detectable HIV RNA. These levels of detectable
HIV RNA were statistically similar, although a trend toward an
association between $48-hour interruptions and detectable HIV
RNA was seen (X
2 2.5, p=0.11).
Correlation of Mean Adherence Measures and Log HIV
RNA
Spearman correlations among all measures of adherence and
log HIV RNA are shown in Table 4. Significant correlations were
seen between the two subjective measures of mean adherence
(three-day recall and VAS, r=0.39, p,0.0001), as well as between
MEMS and all other adherence measures (r=0.24 with three-day
recall, p=0.009; r=0.19 with VAS, p=0.04; r=0.41 with
unannounced pill counts/liquid formulation weights, p,0.0001)
over the one year study period. When comparing log HIV RNA
with adherence in the month prior to the HIV RNA measure-
ments, a statistically significant association was seen only with
MEMS and log HIV RNA at the six-month time point (r=20.25,
p=0.04). Log HIV RNA at six months was also significantly
correlated with log HIV RNA at 12 months (r=0.60, p,0.0001).
Predictors of Adherence
MEMS adherence data was used as the outcome for the
primary adherence analysis because it is an objective measure and
significantly correlated with log HIV RNA. Table 5 presents the
multivariable correlates of ,90% MEMS adherence, including all
Figure 1. Study participants.
doi:10.1371/journal.pone.0036737.g001
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missing values). Hospitalization of the child in the past three
months (adjusted odd’s ratio [AOR] 3.0, 95% confidence interval
[CI] 1.6–5.5; p=0.001), any use of liquid formulations (AOR 1.4,
95% CI 1.0–2.0, p=0.04), and caregiver’s use of alcohol (AOR
3.1, 95% CI 1.8–5.2; p,0.0001) were associated with ,90%
MEMS adherence. The child’s use of co-trimoxazole (AOR 0.5,
95% CI 0.4–0.9; p=0.009), caregiver use of ART (AOR 0.6, 95%
CI 0.4–0.9; p=0.03), possible caregiver depression (AOR 0.6,
95% CI 0.4–0.8; p=0.0001), and caregiver feeling ashamed of the
child’s HIV status (AOR 0.5, 95% CI 0.3–0.6; p,0.0001) were
protective against ,90% MEMS adherence.
Table 6 presents the multivariable correlates of the presence of
$48-hour interruptions in MEMS adherence data, including all
variables with p,0.10 on univariable analysis (N=82 due to
missing values). Change in drug manufacturer (AOR 4.1, 95% CI
1.5–11.5; p=0.009) and any caregiver alcohol use (AOR 5.5, 95%
CI 2.8–10.7; p,0.0001) were associated with the presence of $48-
hour interruptions by MEMS, while use of second line ART (AOR
0.3, 95% CI 0.1–0.99, p=0.049) and increasing household asset
index (AOR 0.7; 95% CI 0.6–0.9; p,0.0007) were protective
against $48-hour interruptions.
Discussion
Multiple subjective and objective measures reveal high median
adherence among Ugandan children receiving ART through an
HIV/AIDS clinic in a rural, regional referral hospital. However,
the fact that 57% of the children have $48 hour interruptions,
36.3% have detectable HIV RNA, and 30% have ,90%
adherence by MEMS indicates that a better understanding of
adherence and adherence interventions are needed.
This study identified multiple factors that may be important for
adherence success in HIV-infected children in developing settings.
First, several associations suggest that a well-established medica-
tion taking routine is protective against poor adherence (defined as
,90% MEMS and/or the presence of $48-hour interruptions in
MEMS), which is consistent with other pediatric studies of HIV
[5,32] and asthma treatment [33,34]. Co-trimoxazole use may
reflect the importance of children developing effective routines
applicable to ART adherence by taking co-trimoxazole to prevent
opportunistic and other infections in the months prior to starting
ART. While not retained in the multivariable models, the
protective effects of a place to keep ART and taking ART at
enrollment also support the importance of an established
medication taking routine. Although treatment fatigue is a poten-
tial concern for children as their experience with ART lengthens
[18], no decrease in adherence was seen over the one year of
follow up in this study. The protective effect of second line ART
may also reflect the role of treatment experience, albeit likely after
initial adherence challenges. Additionally, changes in the ARV
manufacturer and use of liquid formulations were associated with
poor adherence. While some drug changes involved fixed drug
combinations, which have been shown to increase adherence
[35,36], others were due to the child’s growth and development, as
well as partial stock outs. Liquid formulations were often used as
a means of maintaining the child’s regimen. Regardless of the
reasons behind these changes, the association with poor adherence
suggests that caregivers may have had trouble understanding the
change in their dosing routine.
Study findings additionally support for the role of the caregiver
in establishing a medication taking routine. The protective effect of
caregiver use of ART suggests that caregivers taking ART
themselves may have established, effective means for adherence,
which can then be passed on to the children. The association of
caregiver alcohol use with poor adherence may indicate disruption
of this routine when the caregiver is intoxicated. A similar
association between caregiver alcohol use and poor adherence for
the child was seen in a recent South African study [37]. Alcohol
use is also a common cause of poor adherence among adults taking
ART [38], and this effect likely transfers to the child’s adherence.
Additionally, the protective effect of increasing household assets
against adherence interruptions may reflect the caregivers’ ability
to overcome structural challenges in obtaining medications.
Figure 2. Detectable HIV RNA by ART history at enrollment.
doi:10.1371/journal.pone.0036737.g002
Table 2. Median adherence for the cohort by multiple
measures.
N Median
3-day recall 119 100.0 (99.5–100.0)
30-day VAS 120 97.4 (93.0–100.0)
Unannounced pill counts/liquid formulation
weights
117 97.3 (92.0–100.3)
MEMS 115 96.3 (88.5–99.1)
The interquartile range is shown in parentheses.
VAS = visual analog scale.
doi:10.1371/journal.pone.0036737.t002
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were ashamed of their child’s HIV status had lower odds of poor
adherence. These findings may initially appear counter intuitive.
For example, previous studies in Uganda, Ethiopia, and the US
suggest a negative correlation between depression and adherence
[39,40,41]; however, a South African study found no such
association [37]. The differences among these studies and the
current study may be due to varying cultural factors and/or
measurement of depression. Importantly, the Hopkins Checklist
used in this study assesses depressive symptoms and has been
validated with a grief syndrome in Rwanda [25]. It does not
diagnose clinical depression (i.e. major depressive disorder) per se.
Moreover, the role of depression in adherence behavior is
complex, especially when considering the caregiver-child dyad.
Factors, such as guilt in the setting of vertical transmission, may
manifest as depression [18], rather than more typical symptoms
like hopelessness and psychomotor retardation.
Among the caregivers in this study, possible depression and
shame may actually reflect positive motivational factors for
caregivers to promote ART adherence in their children. For
example, the most commonly endorsed symptom, ‘‘worrying too
much about things’’. Worry, as well as shame, could reflect an
underlying concern and motivation to prevent poor outcomes in
their children. This hypothesis should not be interpreted as an
endorsement of depression and shame; further qualitative study is
needed to understand this complex issue.
Third, the study also found that hospitalization was associated
with poor adherence, which likely reflect adherence challenges
prior to participation in this study. Interestingly, another Ugandan
study found the opposite association on a cross-sectional analysis,
Table 3. Distribution of median adherence by participant using multiple measures.
3-day recall 30-day VAS
Unannounced pill counts/liquid
formulation weights MEMS
Median adherence (%) N % N % N % N %
100 87 73.1 31 25.8 33 28.1 23 20.0
$95–,100 19 16.0 51 42.5 39 33.3 41 35.7
$90–,95 9 7.6 23 19.2 23 19.7 17 14.8
$80–,90 3 2.5 13 10.8 19 16.2 24 20.9
,80 1 0.8 2 1.7 3 2.6 10 8.7
VAS = visual analog scale.
doi:10.1371/journal.pone.0036737.t003
Table 4. Correlation among adherence measures and with HIV RNA.
3-day recall 30-day VAS
Unannounced
pill counts/liquid
formulation weights MEMS
Log HIV RNA at 6
months
Log HIV RNA at 12
months
Mean value 98.7% 95.7% 96.1% 93.1% – –
3-day recall – r=0.39 r=0.05 r=0.24 r=0.12 r=0.15
p,0.0001 p=0.60 p=0.009 p=0.35 p=0.21
N=119 N=117 N=115 N=73 N=80
30-day VAS – – r=20.04 r=0.19 r=20.09 r=0.05
p=0.64 p=0.04 p=0.49 p=0.67
N=117 N=115 N=73 N=80
Unannounced pill count/
liquid formulation weights
–– – r=0.41 r=0.14 r=0.07
p,0.0001 p=0.28 p=0.58
N=114 N=72 N=80
MEMS – – – – r=20.25 r=0.00
p=0.04 p=0.99
N=73 N=80
Log HIV RNA 6 months – – – – – r=0.60
p,0.0001
N=70
Log HIV RNA 12 months – – – – – –
Adherence measures are compared with each other as means for all participants over the duration of the study. Comparisons between mean adherence measures and
log HIV RNA reflect adherence in the month prior to the HIV RNA measurement. The first set of values in each box indicates the Spearman correlation coefficient (r).
VAS = visual analog scale.
Bold indicates p,0.05.
doi:10.1371/journal.pone.0036737.t004
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Univariable Multivariable
Child characteristics
Age .5 years 0.9 (0.7–1.1; p=0.37) 0.9 (0.7–1.3; p=0.58)
Taking ART at enrollment 0.6 (0.4–0.8; p=0.001) 1.0 (0.6–1.6; p=0.89)
Enrollment CD4 percentage 0.98 (0.98–0.99; p,0.0001) 1.01 (0.99–1.02; p=0.41)
Prior use of co-trimoxazole 0.9 (0.6–1.2; p=0.36) 0.5 (0.4–0.9; p=0.009)
Prior hospitalizations 1.8 (1.1–2.8; p=0.02) 3.0 (1.6–5.5; p=0.001)
Regimen characteristics
Change in drug formulation 0.9 (0.7–1.3; p=0.65) 1.5 (0.9–2.4; p=0.08)
Any use of liquid formulations 1.5 (1.2–1.9; p=0.0004) 1.4 (1.0–2.0; p=0.04)
Caregiver characteristics
Use of ART 0.9 (0.7–1.1; p=0.20) 0.6 (0.4–0.9; p=0.03)
Any alcohol use 2.5 (1.7–3.7; p,0.0001) 3.1 (1.8–5.2; p,0.0001)
Possible depression 0.6 (0.5–0.8; p=0.0001) 0.6 (0.4–0.8; p=0.001)
Ashamed of child’s HIV status 0.8 (0.6–0.95; p=0.02) 0.5 (0.3–0.6; p,0.0001)
Household/community characteristics
Place to keep ART 0.4 (0.2–0.8; p=0.009) *
Minutes to travel to clinic 1.0 (1.0–1.0; p=0.19) 1.00 (1.00–1.01; p=0.99)
Cost to travel to clinic 1.0 (1.0–1.0; p=0.32) 1.00 (1.00–1.01; p=0.13)
Values indicate odds ratios with 95% confidence intervals in parentheses.
*Could not be estimated in the multivariable model due to inadequate variation in values.
Bold indicates p,0.05.
doi:10.1371/journal.pone.0036737.t005
Table 6. Predictors of $48-hour interruptions MEMS adherence included in the multivariable model.
Univariable Multivariable
Child characteristics
Age (one year increase) 1.1 (0.99–1.2; p=0.07) 1.03 (0.9–1.2; p=0.66)
Enrollment CD4 percentage 0.9996 (0.9993–0.9999; p=0.02) 1.0003 (0.9998–1.0007; p=0.29)
Attending school 0.6 (0.4–0.9; p=0.02) 1.1 (0.6–2.0; p=0.77)
Regimen characteristics
Change in drug manufacturer 0.98 (0.5–1.8; p=0.96) 4.1 (1.5–11.5; p=0.009)
Any use of liquid formulations 1.7 (1.2–2.6; p=0.007) 1.7 (0.97–3.1; p=0.06)
Use of second line ART 0.3 (0.1–0.96; p=0.04) 0.3 (0.1–0.99; p=0.049)
Caregiver characteristics
Greater than primary school 0.4 (0.3–0.7; p=0.001) 0.6 (0.3–1.1; p=0.13)
Employed 0.6 (0.4–0.9; p=0.006) 0.8 (0.5–1.2; 0.26)
Any alcohol use 4.9 (3.1–7.9; p,0.0001) 5.5 (2.8–10.7; p,0.0001)
Household/community characteristics
Place to keep ART 0.2 (0.1–0.4; p,0.0001) 0.3 (0.1–1.01; p=0.05)
Minutes to travel to clinic 0.993 (0.986–0.999; p=0.02) 1.004 (0.99–1.01; p=0.41)
Disclosure to the community 0.6 (0.4–0.8; p=0.01) 0.6 (0.4–1.1; p=0.10)
Asset index 0.7 (0.6–0.8; p,0.0001) 0.7 (0.6–0.9; p=0.0007)
# people in the household 0.9 (0.8–0.95; p=0.002) 1.01 (0.9–1.1; p=0.90)
# other children in the household 0.9 (0.8–0.98; p=0.02) 0.9 (0.8–1.1; p=0.41)
Having to sell property 1.6 (1.1–2.4; p=0.03) 1.3 (0.8–2.3; p=0.28)
Values indicate odds ratios with 95% confidence intervals in parentheses.
*Could not be estimated in the multivariate model due to inadequate variation in values.
Bold indicates p,0.05.
doi:10.1371/journal.pone.0036737.t006
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in these results may be due to inclusion of relatively healthier
children in this study.
MEMS appeared to be the best measure of adherence in this
study for several reasons. First, as an objective measure, MEMS
captures presumed dosing whether it is provided by a caregiver or
initiated by the child; subjective measures often fail to accurately
reflect both sources of information [18]. Second, MEMS was
significantly correlated with HIV RNA, consistent with other
pediatric studies in Africa [5,17]. Third, MEMS had the widest
distribution of adherence, which suggests that it may be better able
to identify individuals with incomplete adherence. Additionally,
MEMS was a feasible measure despite the common use of liquid
formulations. MEMS, however, only had a modest correlation
with log HIV RNA at one time point, which may be explained
either by high rates of missing HIV RNA data, gaps in adherence
which occurred prior to monitoring, and/or relatively limited
variation in adherence values. Additionally, due to their expense,
MEMS is not a practical outside a research setting.
Other adherence measures had distinct shortcomings. Un-
announced pill counts/liquid weights were resource intensive and
not associated with HIV RNA, possibly due to the inability to
accurately track how much medication was dispensed during refill
visits. The subjective measures of three-day recall and 30-day VAS
did not correlate with HIV RNA, likely because of the minimal
variance and the overestimation common with these measures
[42]. The challenges seen with each adherence measure support
a previous study reporting inadequate methods for use in resource-
limited settings [43] and underscore the need for new approaches.
The type of adherence estimate is also important for un-
derstanding the relationship between adherence and viral
suppression, as well as predictors of adherence behavior. The
children in this study appear to have had sufficiently high median
adherence to suppress viral replication with most modern, potent
regimens [30]. The high levels of detectable HIV RNA in children
without ART prior to study enrollment, however, indicate that
high median adherence estimates do not ensure viral suppression.
Although $48-hour interruptions and detectable HIV RNA were
not significantly correlated in this study, the trend toward a positive
association suggests such a relationship may be seen in larger
sample sizes. Unfortunately, drug resistance data were not
available for this analysis to better characterize the relationship
between adherence interruptions and detectable HIV RNA.
Surveillance data from Botswana suggest background HIV drug
resistance in the region was likely to be very low at the time of the
study, although rates in Uganda are unknown [44]. Further study
of adherence interruptions could be facilitated by real-time
adherence monitoring and HIV RNA testing [45], which may
yield better information on which individuals are at risk for
treatment failure. Additionally, predictors of adherence behavior
differed somewhat between median adherence and $48-hour
interruptions, suggesting that the factors influencing overall
adherence behavior and interruptions in that behavior may be
distinct to some extent.
This study has several limitations. First, the generalizability of
the study results may be limited by the use of a stable, relatively
healthy patient population living within 20 kilometers of the clinic.
The same logistic considerations that made data collection
problematic for children living farther than 20 kilometers from
the clinic might have also impeded them in returning for pill
dispensation and other care. Additional research is needed to
better understand populations lost from care and how best to
promote their retention in care and adherence to therapy. Second,
the many adherence measures used in this study may have affected
the adherence behavior of the study participants (i.e. the
Hawthorne effect). While possible, adherence behavior altered
by MEMS monitoring has been shown to revert to baseline within
several weeks [46], and this study lasted one year. Third, the
sample size, especially when considering missing data, may not be
adequate to fully analyze correlates of adherence. Fourth, the
exact nature of the hospitalizations is not known and the impact
on adherence is speculative. Finally, the some of the measurement
scales were developed and validated in developed countries and
may not fully apply to this setting.
In conclusion, this study indicates that children in a rural, sub-
Saharan African setting appear to have adequate median
adherence to ART for viral suppression. However, the consider-
able number of interruptions in adherence and a high degree of
detectable HIV RNA raise concern about their adherence and the
long-term treatment success in this population. Interventions
geared toward establishing good medication routines and addres-
sing underlying motivational factors for the caregivers, such as fear
of poor outcomes, may be potential means to promote successful
adherence to ART.
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